Active Ingredient History
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
---|
Carcinoma, Non-Small-Cell Lung (approved 2020)
Thyroid Neoplasms (approved 2020)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Colonic Neoplasms (Phase 1)
Ependymoma (Phase 2)
Fibrosarcoma (Phase 1/Phase 2)
Glioma (Phase 2)
Healthy Volunteers (Phase 1/Phase 2)
Hepatoblastoma (Phase 2)
Histiocytosis, Langerhans-Cell (Phase 2)
Leukemia, Hairy Cell (Phase 2)
Liver Diseases (Phase 1/Phase 2)
Lung Neoplasms (Phase 2)
Lymphoma (Phase 2)
Lymphoma, Non-Hodgkin (Phase 2)
Medulloblastoma (Phase 2)
Neoplasm Metastasis (Phase 2)
Neoplasms (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 2)
Osteosarcoma (Phase 2)
Renal Insufficiency (Phase 1)
Rhabdoid Tumor (Phase 2)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Thyroid Cancer, Papillary (Phase 2)
Thyroid Neoplasms (Phase 3)
Wilms Tumor (Phase 2)
Trial | Phase | Start Date | Organizations | Indications |
---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue